BWAY

BrainswayD

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$18.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$13.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$10.00

Analysis reference price unavailable

Analysis 2026-04-15 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

Recent primary-source flow is constructive on fundamentals and product access, but the evidence set remains narrow and mostly company-led. That supports a monitoring-style stance rather than a strong bullish call: the company has credible growth signals, yet the stock already trades above the packet's sell-side median target and the deterministic prior remains neutral with very high uncertainty [#PR-2026-03-11] [#PR-2026-01-07].

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-15eventMid-year proof point against 2026 guideHigh impact

BrainsWay guided for 2026 revenue of $66-$68 million, operating income margin of 13%-14%, and adjusted EBITDA of $12-$14 million after reporting 27% 2025 revenue growth, roughly $70 million of remaining performance obligations, and an installed base of about 1,700 systems; the next meaningful execution readout needs to confirm that this growth is converting beyond a strong Q4 print [#PR-2026-03-11].

2026-12-31catalystSWIFT reimbursement and provider adoption expansionHigh impact

The first stated coverage policy for accelerated SWIFT Deep TMS and newly published SWIFT clinical data improve the commercial case for faster-treatment workflows, but broader payer adoption still has to materialize before the market can underwrite a sustained volume step-up [#PR-2026-01-07] [#PR-2026-03-04].

2026-12-31catalystStrategic investment portfolio adds optional upside but raises execution questionsHigh impact

Recent milestone investments in Axis and Neurolief show management is trying to widen distribution and total addressable market, including home-use neuromodulation exposure, but these assets remain option-like and are not yet a clean substitute for core Deep TMS operating execution [#PR-2026-03-19] [#PR-2026-03-26].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology